Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients


This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) presented interim results of the Phase 3 randomized SEQUOIA study which evaluated the efficacy and safety of zanubrutinib versus BR in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients without the high-risk mutation,17p deletion
This is huge. This is game changing. This was one of the six late-breaking abstracts from ASH (American Society of Hematology) 2018 Annual Meeting and Congress that were selected because they reflect the most important, latest research in hematology and change how we manage heme malignancies. Dr. Tait Shanafelt